Defendants shall be punished by a fine of KRW 15,000,000.

Defendant

If A does not pay the above fine, 100.

Punishment of the crime

Defendant A, as an internal director of (State)B, is a corporation established for the purpose of manufacturing medical treatment in France. (State) Defendant A, as an internal director of the said corporation, is a corporation established for the purpose of manufacturing medicine in France.

1. Any person who files an import declaration on goods in violation of the Customs Act shall be prohibited from importing goods without meeting requirements for permission, approval, recommendation, certification, or other conditions necessary for import pursuant to Acts and subordinate statutes or importing goods by unlawful means;

Defendant

A around March 12, 2013, the Ministry of Food and Drug Safety received from the Korea Food and Drug Safety the license for imported pharmaceutical products with prescription drugs, “N-Dymylide,” or “DAC,” which is “N-Dymylide,” or “N-Dymylide,” from the Ministry of Food and Drug Safety. Meanwhile, in order to import pharmaceutical products as identified by the Ministry of Trade, Industry and Energy, according to the Ministry of Food and Drug Safety’s notification, it is required to file a standard customs clearance report with the Director of the Korea Food and Drug Safety. On September 9, 2013, Defendant A filed a report with the Director of the Korea Food and Drug Safety on the imported pharmaceutical products with the Korea Food and Drug Safety (“N-Dympicoide” or “Dympicocococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococococo, “.

In addition, the defendant A is marked in attached Table 1 from that time until January 5, 2018.